Gt Biopharma, Inc. · NASDAQ:GTBP
Gt Biopharma — ESMO Congress 2021
10 slides from Gt Biopharma's conference presentation, Sep 17, 2021
Slide 1: GTB-3550 TriKE safely activates and delivers IL-15 to NK cells
GTB-3550 TriKE™ safely activates and delivers IL-15 to NK cells, but not T cells, in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing HER2 or B7H3
Slide 2: Disclosures
Disclosures GT BioPharma ◦ SAB, Research Support, Consulting, Stock options Fate Therapeutics ◦ Research Support, Consulting, Stock options OnkImmune, Nektar ◦ SAB Vycellix ◦ Consulting, Stock options
Slide 3: Allogenic NK Cell Adoptive Transfer: Two Decades and Hundreds of Patients
Allogenic NK Cell Adoptive Transfer: Two Decades and Hundreds of Patients Relapsed/refractory AML PB Apheresis Cy 60 mg/kg x 2 Flu 25 mg/m2 x 5 Surge IL-15 NK-enriched product CD3/CD19-depletion Overnight IL-2 or IL-15 1Miller et al, Blood, 2005; 2Bachanova et al, Blood 2014; 3Cooley et al, Blood Ad
Slide 4: Allogenic NK Cell Adoptive Transfer: Two Decades and Hundreds of Patients
Allogenic NK Cell Adoptive Transfer: Two Decades and Hundreds of Patients Relapsed/refractory AML PB Apheresis Cy 60 mg/kg x 2 Flu 25 mg/m2 x 5 Surge IL-15 NK-enriched Lessons learned: More product specificity is needed CD3/CD19-depletion Overnight IL-2 or IL-15 TriKE 1Miller et al, Blood, 2005; 2Ba
Slide 5: Replacement Of scFv With Camelid VHH Single Domain Sequences
Replacement Of scFv With Camelid VHH Single Domain Sequences VHH αCD16 Efficient VH VL αCD33 IL-15
Slide 6: camTriKE better activates NK Cells but not T Cells
camTriKE better activates NK Cells but not T Cells
Slide 7: 2nd Generation TriKE Function In Vivo
2nd Generation TriKE Function In Vivo
Slide 8: Cam16/IL15/scFv HER2 TriKE Highly Effective Against Ovarian Cancer
Click to edit Master Cam16/IL15/scFv title Highly HER2 TriKE style Effective Against Ovarian Cancer
Slide 9: cam1615camB7H3 TriKE Pan Solid Tumor Targeting
Click to edit Master title style cam1615camB7H3 TriKE Pan Solid Tumor Targeting PE cam IL15 cam B7H3+ His tag Tumor Percent CD107a+ NK Cells Percent IFN-gamma+ NK Cells 80 40 Percent NK Cells * * Percent NK Cells 60 30 40 20 20 10 0 0 ly nM 5 5 T O E e E O ly 5 T 5 -1 -1 +W iK +K e on iK -1 -1 +W iK
Slide 10: Team Science
Team Science University of Minnesota Laboratory Faculty/MDs GMP Facility Martin Felices Mark Juckett David McKenna, MD Daniel Vallera Daniel J Weisdorf Darin Sumstad Frank Cichocki John Wagner Diane Kadidlo Nick Zorko Bruce Blazar William Sharkey Bruce Walcheck Claudio Brunstein Andy Sicheneder Aime